Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome associated with fumarate hydratase (FH) gene mutation leading to defective DNA double-strand break repair mechanism. Although these tumours have an aggressive presentation, they respond well to targeted ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomar, Shubham, Kashyap, Lakhan, Kapoor, Akhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300402/
https://www.ncbi.nlm.nih.gov/pubmed/35919231
http://dx.doi.org/10.3332/ecancer.2022.1404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300402/
https://www.ncbi.nlm.nih.gov/pubmed/35919231
http://dx.doi.org/10.3332/ecancer.2022.1404

Ejemplares similares